Concepedia

Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study

Paolo Verdecchia, Antonio D’Onofrio, Vincenzo Russo, Francesco Fedele, Francesco Maria Adamo, Giulia Benedetti, Fabio Ferrante, Corrado Lodigiani, Francesco Paciullo, Adolfo Aita,

Journal of Cardiovascular Medicine · 2018 · 16 citations · 30 references

DOI

Abstract

In real-life conditions, NVAF patients treated with apixaban show rates of treatment discontinuation and major bleedings, which are comparable to those found in the ARISTOTLE pivotal study, thus supporting its external validity.

References

30

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf et al. · New England Journal of Medicine · 2009 · 11.1K citations · Full text

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine · 2011 · 9.3K citations · Full text

Apixaban versus Warfarin in Patients with Atrial Fibrillation

Christopher B. Granger, John H. Alexander, John J.V. McMurray et al. · New England Journal of Medicine · 2011 · 8.8K citations · Full text

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

Philip A. Wolf, Robert D. Abbott, W B Kannel · Stroke · 1991 · 7.4K citations

, , +20

Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

European Heart Journal · 2010 · 5.8K citations · Full text